JP2016515407A - Ecm移植組成物および方法 - Google Patents
Ecm移植組成物および方法 Download PDFInfo
- Publication number
- JP2016515407A JP2016515407A JP2016502888A JP2016502888A JP2016515407A JP 2016515407 A JP2016515407 A JP 2016515407A JP 2016502888 A JP2016502888 A JP 2016502888A JP 2016502888 A JP2016502888 A JP 2016502888A JP 2016515407 A JP2016515407 A JP 2016515407A
- Authority
- JP
- Japan
- Prior art keywords
- submucosa
- tissue
- sugar
- composition according
- ecm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 title claims abstract description 58
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 115
- 235000000346 sugar Nutrition 0.000 claims abstract description 53
- 210000001519 tissue Anatomy 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims description 103
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 62
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 62
- 210000004876 tela submucosa Anatomy 0.000 claims description 48
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 29
- 239000005715 Fructose Substances 0.000 claims description 28
- 229930091371 Fructose Natural products 0.000 claims description 28
- 239000012736 aqueous medium Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 210000000813 small intestine Anatomy 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 206010040943 Skin Ulcer Diseases 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 231100000019 skin ulcer Toxicity 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 206010072170 Skin wound Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000037314 wound repair Effects 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 239000011159 matrix material Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- -1 fructose or glucose Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000109 continuous material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 108010070228 surgisis Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本願は、その全体が本明細書に引用により援用される2013年3月15日に出願され「ECM IMPLANT COMPOSITIONS AND METHODS(ECM移植組成物および方法)」と題された米国仮特許出願第61/802,113号の利益を主張する。
本発明は、一般的には医療用組成物の分野に属し、具体的な側面では細胞外マトリクス材料を組込んだ医療用組成物に関する。
ある局面において、本開示は、粒状ECM組織材料を含む成形可能な医療用組成物に関する。成形可能な組成物は、たとえば形状保持であるが成形可能なパテ材料であってもよい。
次に、本開示の原理の理解を促すために、図面に示される実施形態を参照し、その説明のために特定の用語を使用する。しかしながら、それによって請求項の範囲を限定することを意図しているのではないことが理解されるであろう。また、示されている装置に対する代案および変形ならびに本明細書に示される開示の原理のさらに他の応用に、本開示の関連技術における当業者は通常想到すると考えられることが、理解されるであろう。
細胞外マトリクス粒状物の再水和時間
凍結させた粒状細胞外マトリクス組織(粉砕細分した小腸粘膜下組織)を出発材料として準備した。この凍結させた粒状物を1つ当たり10gの部分に分割し解凍した。50mg、100mg、200mg、または500mgのD−フルクトースUSPを、水和した粒状ECM組織の各10gの部分(乾燥重量で約1gの粒状ECM組織に等しい)に加えた。これら組合された材料を、2つのルアーロックシリンジによって前後に混合し、3.5”×3.5”×1”のポリスチレン計量ボートに供給した。次に、この混合物を計量ボート内で凍結乾燥することにより、平坦な乾燥した多孔体を作成した。
細胞外マトリクス粒状物の血清取込み
実施例1と同様に調製した乾燥体を、最初に、実施例1で説明したように1xPBS中で6mLの4%BSAを用いて再水和した。再水和したものに、試料が粘着形状を保持できなくなるまで、追加の流体を1mLずつ加えた。各試料がその粘着形状を失う前に取込むことができた流体の総量を記録した。血清取込みアッセイの結果は図4で報告されている。例示として、200mgのフルクトースを含有する試料は、平均9.6mLの流体を吸収しながら粘着性を保つことができたが、フルクトースなしの制御試料が吸収した流体は平均9.4mLであった。
Claims (48)
- 材料を調製する方法であって、
粒状細胞外マトリクス組織と糖と液体とを含む材料の混合物を乾燥して乾燥体を形成することを含む、方法。 - 前記乾燥は凍結乾燥を含む、請求項1に記載の方法。
- 前記混合物を金型に入れることをさらに含み、前記乾燥は前記混合物を前記金型に入れた状態で行なわれる、請求項1または2に記載の方法。
- 前記乾燥体の質量は約0.5g〜約5gである、請求項1〜3のいずれか一項に記載の方法。
- 前記粒状細胞外マトリクス組織は粘膜下組織を含む、請求項1〜4のいずれか一項に記載の方法。
- 前記粘膜下組織は、腸粘膜下組織、膀胱粘膜下組織、胃粘膜下組織、または小腸粘膜下組織(SIS)を含む、請求項5に記載の方法。
- 前記乾燥体を滅菌することをさらに含む、請求項1〜6のいずれか一項に記載の方法。
- 前記糖はフルクトースを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記糖は少なくとも50%のフルクトースで構成される、請求項8に記載の方法。
- 粒状ECM組織と糖との重量比は、約10:1〜約1:1、または約5:1〜約1:1、または約3:1〜約1:1である、請求項1〜9のいずれか一項に記載の方法。
- 患者を治療するための材料を調製する方法であって、
粒状細胞外マトリクス組織と糖との混合物を含む乾燥体を再水和することを含む、方法。 - 前記再水和は、形状保持であるが成形可能なパテを形成するのに十分な程度行なわれる、請求項11に記載の方法。
- 前記再水和は、水性媒体を前記乾燥体と合わせることを含む、請求項11または12に記載の方法。
- 前記水性媒体は、血液もしくは血液分画物であるかまたはこれらを含む、請求項13に記載の方法。
- 前記血液もしくは血液分画物は、前記材料で治療される対象にとって自己由来のものである、請求項14に記載の方法。
- 前記水性媒体は血清であるかまたは血清を含む、請求項14または15に記載の方法。
- 前記水性媒体の体積は5ml〜約10mlである、請求項13〜16のいずれか一項に記載の方法。
- 前記材料を患者に投与することをさらに含む、請求項11〜17のいずれか一項に記載の方法。
- 粒状細胞外マトリクス(ECM)組織と糖とを含む混合物を含む医療用組成物。
- 前記混合物は乾燥した多孔体に存在する、請求項19に記載の医療用組成物。
- 前記乾燥した多孔体は凍結乾燥された材料である、請求項20に記載の医療用組成物。
- 粒状ECM組織と糖の重量比は、約10:1〜約1:1、または約5:1〜約1:1、または約3:1〜約1:1である、請求項19〜21のいずれか一項に記載の医療用組成物。
- 前記組成物は形状保持であるが成形可能なパテである、請求項19〜22のいずれか一項に記載の医療用組成物。
- 前記混合物は、質量が約0.5g〜約5gの乾燥した多孔体に存在する、請求項19〜22のいずれか一項に記載の医療用組成物。
- 前記粒状細胞外マトリクス組織は粘膜下組織を含む、請求項19〜24のいずれか一項に記載の医療用組成物。
- 前記粘膜下組織は、腸粘膜下組織、膀胱粘膜下組織、胃粘膜下組織、または小腸粘膜下組織(SIS)を含む、請求項25に記載の医療用組成物。
- 前記糖はフルクトースを含む、請求項19〜26のいずれか一項に記載の医療用組成物。
- 前記粒状細胞外マトリクス組織は、前記細胞外マトリクス組織の供給源組織から保持されている少なくとも1つの天然成長因子を含む、請求項19〜27のいずれか一項に記載の医療用組成物。
- 皮膚の傷の治療のための、請求項19〜28のいずれか一項に記載の組成物。
- 皮膚の潰瘍の治療のための、請求項29に記載の組成物。
- 前記乾燥体の質量は約0.5g〜約5gである、請求項1または2に記載の方法。
- 前記粒状細胞外マトリクス組織は粘膜下組織を含む、請求項1または2に記載の方法。
- 前記粘膜下組織は、腸粘膜下組織、膀胱粘膜下組織、胃粘膜下組織、または小腸粘膜下組織(SIS)を含む、請求項1または2に記載の方法。
- 前記乾燥体を滅菌することをさらに含む、請求項1または2に記載の方法。
- 前記糖はフルクトースを含む、請求項1または2に記載の方法。
- 前記糖は少なくとも50%のフルクトースで構成される、請求項35に記載の方法。
- 粒状ECM組織と糖との重量比は、約10:1〜約1:1、または約5:1〜約1:1、または約3:1〜約1:1である、請求項1または2に記載の方法。
- 前記水性媒体は血清であるかまたは血清を含む、請求項14に記載の方法。
- 前記水性媒体の体積は5ml〜約10mlである、請求項13に記載の方法。
- 前記材料を患者に投与することをさらに含む、請求項11または12に記載の方法。
- 前記組成物は形状保持であるが成形可能なパテである、請求項19〜21のいずれか一項に記載の医療用組成物。
- 前記混合物は質量が約0.5g〜約5gの乾燥した多孔体に存在する、請求項19〜21のいずれか一項に記載の医療用組成物。
- 前記粒状細胞外マトリクス組織は粘膜下組織を含む、請求項19〜21のいずれか一項に記載の医療用組成物。
- 前記粘膜下組織は、腸粘膜下組織、膀胱粘膜下組織、胃粘膜下組織、または小腸粘膜下組織(SIS)を含む、請求項43に記載の医療用組成物。
- 前記糖はフルクトースを含む、請求項19〜21のいずれか一項に記載の医療用組成物。
- 前記粒状細胞外マトリクス組織は、前記細胞外マトリクス組織の供給源組織から保持されている少なくとも1つの天然成長因子を含む、請求項19〜21のいずれか一項に記載の医療用組成物。
- 皮膚の傷の治療のための、請求項19〜21のいずれか一項に記載の組成物。
- 皮膚の潰瘍の治療のための、請求項47に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802113P | 2013-03-15 | 2013-03-15 | |
US61/802,113 | 2013-03-15 | ||
PCT/US2014/028750 WO2014144370A1 (en) | 2013-03-15 | 2014-03-14 | Ecm implant compositions and methods |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016515407A true JP2016515407A (ja) | 2016-05-30 |
JP2016515407A5 JP2016515407A5 (ja) | 2017-04-13 |
JP6448615B2 JP6448615B2 (ja) | 2019-01-09 |
Family
ID=50625162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502888A Active JP6448615B2 (ja) | 2013-03-15 | 2014-03-14 | Ecm移植組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10973856B2 (ja) |
EP (1) | EP2968671B1 (ja) |
JP (1) | JP6448615B2 (ja) |
AU (2) | AU2014227561C1 (ja) |
BR (1) | BR112015021343A2 (ja) |
CA (1) | CA2900851C (ja) |
WO (1) | WO2014144370A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018515295A (ja) * | 2015-05-27 | 2018-06-14 | クック リージェンテック エルエルシーCook Regentec Llc | シート状細胞成長足場粒子及び移植片並びにそれらのための方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008509924A (ja) * | 2004-08-12 | 2008-04-03 | アドライフ インコーポレイテッド | 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 |
US20110150998A1 (en) * | 2009-12-22 | 2011-06-23 | Laura-Lee Farrell | Methods For Producing ECM-Based Biomaterials |
JP2011525140A (ja) * | 2008-06-20 | 2011-09-15 | クック・バイオテック・インコーポレイテッド | 複合細胞外マトリックス材料およびそれらから形成される医療製品 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361552A (en) | 1980-09-26 | 1982-11-30 | Board Of Regents, The University Of Texas System | Wound dressing |
US4956178A (en) | 1988-07-11 | 1990-09-11 | Purdue Research Foundation | Tissue graft composition |
US4902508A (en) | 1988-07-11 | 1990-02-20 | Purdue Research Foundation | Tissue graft composition |
US5281422A (en) | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
DE69725592T2 (de) | 1996-08-23 | 2004-08-05 | Cook Biotech, Inc., West Lafayette | Verfahren zur gewinnung einer gereignigten matrix auf kollagenbasis aus submukosa gewebe |
US6379710B1 (en) | 1996-12-10 | 2002-04-30 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
CA2267310C (en) | 1996-12-10 | 2012-09-18 | Purdue Research Foundation | Stomach submucosa derived tissue graft |
US5993844A (en) | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
RU2245722C2 (ru) | 1999-06-22 | 2005-02-10 | Рисерч Дивелопмент Фаундейшн | Усовершенствованное раневое покрытие для улучшения заживления ран |
AU2002320189B2 (en) | 2001-06-28 | 2007-04-26 | Cook Biotech Incorporated | Graft prosthesis devices containing renal capsule collagen |
JP2005505351A (ja) | 2001-10-12 | 2005-02-24 | オステオテック インコーポレーテッド | 改善された骨移植片 |
US7291345B2 (en) | 2002-12-12 | 2007-11-06 | Osteotech, Inc. | Formable and settable polymer bone composite and method of production thereof |
US8021692B2 (en) | 2003-08-25 | 2011-09-20 | Cook Biotech Incorporated | Graft materials containing bioactive substances, and methods for their manufacture |
US20060246033A1 (en) * | 2005-03-02 | 2006-11-02 | Cook Biotech Incorporated | Injectable bulking agent compositions |
US9788821B2 (en) * | 2005-04-29 | 2017-10-17 | Cook Biotech Incorporated | Physically modified extracellular matrix materials and uses thereof |
US20060292227A1 (en) * | 2005-06-23 | 2006-12-28 | Mcpherson Timothy B | Extracellular matrix material particles and methods of preparation |
US10500309B2 (en) * | 2007-10-05 | 2019-12-10 | Cook Biotech Incorporated | Absorbable adhesives and their formulation for use in medical applications |
WO2009086499A2 (en) | 2007-12-28 | 2009-07-09 | Cook Biotech Incorporated | Medical composition including an extracellular matrix particulate |
US8840913B2 (en) * | 2008-03-27 | 2014-09-23 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
-
2014
- 2014-03-14 WO PCT/US2014/028750 patent/WO2014144370A1/en active Application Filing
- 2014-03-14 CA CA2900851A patent/CA2900851C/en active Active
- 2014-03-14 JP JP2016502888A patent/JP6448615B2/ja active Active
- 2014-03-14 EP EP14720392.1A patent/EP2968671B1/en active Active
- 2014-03-14 AU AU2014227561A patent/AU2014227561C1/en active Active
- 2014-03-14 BR BR112015021343A patent/BR112015021343A2/pt active Search and Examination
- 2014-03-14 US US14/211,234 patent/US10973856B2/en active Active
-
2017
- 2017-09-21 AU AU2017232134A patent/AU2017232134B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008509924A (ja) * | 2004-08-12 | 2008-04-03 | アドライフ インコーポレイテッド | 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 |
JP2011525140A (ja) * | 2008-06-20 | 2011-09-15 | クック・バイオテック・インコーポレイテッド | 複合細胞外マトリックス材料およびそれらから形成される医療製品 |
US20110150998A1 (en) * | 2009-12-22 | 2011-06-23 | Laura-Lee Farrell | Methods For Producing ECM-Based Biomaterials |
Also Published As
Publication number | Publication date |
---|---|
US10973856B2 (en) | 2021-04-13 |
WO2014144370A1 (en) | 2014-09-18 |
US20140275290A1 (en) | 2014-09-18 |
EP2968671A1 (en) | 2016-01-20 |
AU2014227561C1 (en) | 2017-12-14 |
JP6448615B2 (ja) | 2019-01-09 |
AU2017232134A1 (en) | 2017-10-12 |
AU2014227561B2 (en) | 2017-06-22 |
EP2968671B1 (en) | 2018-10-10 |
AU2017232134B2 (en) | 2019-02-14 |
CA2900851A1 (en) | 2014-09-18 |
AU2014227561A1 (en) | 2015-10-01 |
CA2900851C (en) | 2021-06-22 |
BR112015021343A2 (pt) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2109444B1 (en) | Bone growth particles and osteoinductive composition thereof | |
Yoshimi et al. | Self-assembling peptide nanofiber scaffolds, platelet-rich plasma, and mesenchymal stem cells for injectable bone regeneration with tissue engineering | |
US20200237955A1 (en) | Bioactive Grafts and Composites | |
CA2721900C (en) | Biocompatible implant | |
JP2015534945A (ja) | 幹細胞を動員および局在化するための組成物および方法 | |
KR20150138157A (ko) | 비-포유류 조직으로부터의 세포제거된 생체재료 | |
EP3417889A1 (en) | Bioactive grafts and composites | |
US8936816B1 (en) | Composition of a bone repair mixture | |
EP2389205B1 (en) | Method of making osteoinductive bone implant | |
US20120195982A1 (en) | Injectible, biocompatible synthetic bone growth composition | |
CA3008798A1 (en) | Soluble bone marrow protein compositions, methods of making, and uses thereof | |
Endres et al. | Angiogenesis and healing with non-shrinking, fast degradeable PLGA/CaP scaffolds in critical-sized defects in the rabbit femur with or without osteogenically induced mesenchymal stem cells | |
JP6448615B2 (ja) | Ecm移植組成物および方法 | |
JP6018477B2 (ja) | 人工骨−軟骨複合体及びその製造方法 | |
US20190151501A1 (en) | Bioactive grafts and composites | |
JP2014230685A (ja) | 歯周組織形成用材料 | |
US20240024534A1 (en) | Bioactive grafts and composites | |
EP3927388A1 (en) | Decellularized muscle matrices and methods for making and using same | |
EP4304669A1 (en) | Scaffold for bone regeneration and manufacturing method thereof | |
CN112717204A (zh) | 自体骨移植物活性替代物组合物、制备方法及应用 | |
De et al. | Orthopaedic Surgery: Basic Science and Clinical | |
AU2014218483A1 (en) | Bioactive grafts and composites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170309 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171219 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181022 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6448615 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |